Cell viability is one of the clearest indicators of stem cell quality. Learn why viable, functional MSCs are central to safe and meaningful regenerative outcomes.
In mesenchymal stem cell (MSC) therapy, the number of cells delivered is only part of the story. What truly matters is how many of those cells are alive and biologically active at the moment of treatment.
Cell viability describes the percentage of cells in a sample that are still alive and functional. In the context of MSC therapy, this is one of the core indicators of product quality. A high viability percentage suggests that most delivered cells are capable of carrying out their biological roles. Low viability indicates that a meaningful fraction of the dose is non-functional cellular material. For this reason, viability is reviewed at multiple points across cell processing, not only at the final step.
Several laboratory methods are used to measure cell viability in MSC preparations. Trypan blue exclusion is a simple dye-based method that distinguishes living from dead cells under a microscope. Flow cytometry with viability dyes provides more precise and quantitative readings. Automated cell counters are commonly used for fast routine checks during expansion. Reputable laboratories typically combine more than one method and document the result for each batch.
Only living MSCs can release the growth factors, cytokines, and exosomes that drive their regenerative effects. Dead cells cannot perform paracrine signaling, modulate immune activity, or migrate to areas of injury. This means that viability directly limits the biological dose a patient actually receives. Two preparations with the same total cell count can deliver very different therapeutic value. Standardized viability thresholds help align expectations between laboratories, clinicians, and patients.
When too many dead cells are present, the body must clear that cellular debris. Excessive debris can trigger inflammatory responses that work against the goal of treatment. There is also a risk of releasing intracellular contents that may activate immune cells. For these reasons, regulatory and clinical standards typically require viability above 90% for MSC therapy products. Maintaining high viability is therefore a safety issue, not only an efficacy issue.
Cell viability can be reduced at any stage of processing if conditions are not well controlled. Source tissue quality, donor health, and time to processing all influence the starting cell population. Suboptimal culture media, oxygen levels, or temperature can cause stress during expansion. Cryopreservation and thawing are particularly sensitive steps where many cells can be lost. Excessive time between thawing and administration further reduces the number of living cells in the dose.
Well-run laboratories operate under GMP-grade processes with documented standard operating procedures. Equipment such as incubators, centrifuges, and freezers is monitored and maintained on defined schedules. Cell handling steps are minimized and standardized to limit mechanical and thermal stress. Staff are trained specifically in MSC processing rather than treating it like generic cell culture. Each batch is accompanied by a certificate of analysis that includes viability results.
Patients considering MSC therapy can reasonably ask how cell viability is measured and reported. Requesting a certificate of analysis is a fair and increasingly common step. Understanding how cells are stored and prepared on the day of treatment is also useful. The time between thawing and infusion is an important practical detail to confirm. Clear, documented answers are one sign that a clinic takes cell quality seriously.
Cell counts alone can sound impressive, but viability is a more meaningful measure of what a patient receives. High-quality MSC therapy depends on cells that are not only present but alive and biologically ready to work.